GOLT1B inhibitors constitute a chemical class of compounds specifically designed to target and modulate the activity of the Golgi transport 1B protein, abbreviated as GOLT1B. These inhibitors play a crucial role in elucidating the function and regulatory mechanisms of GOLT1B within the context of cellular processes. GOLT1B itself is a critical component of the Golgi apparatus, a membrane-bound organelle found in eukaryotic cells responsible for the modification, sorting, and transport of proteins and lipids to their final cellular destinations. The Golgi apparatus plays a central role in cellular trafficking and secretion, making GOLT1B a key player in maintaining cellular homeostasis and proper organelle function.
GOLT1B inhibitors are designed to interact with GOLT1B at the molecular level, disrupting its enzymatic activity and impeding its role in protein and lipid trafficking. These inhibitors often act through various mechanisms, such as competitive or non-competitive binding to the active site of GOLT1B. By doing so, they hinder the ability of GOLT1B to process and transport cargo molecules within the Golgi apparatus, ultimately affecting the sorting and secretion of proteins and lipids. As a result, researchers and scientists utilize GOLT1B inhibitors as invaluable tools in cell biology and molecular research to unravel the intricacies of Golgi function, cellular trafficking, and protein processing. These compounds enable the manipulation of GOLT1B-dependent processes, shedding light on the fundamental mechanisms governing intracellular transport and providing valuable insights into cellular biology. Additionally, GOLT1B inhibitors have applications in drug discovery, as a deeper understanding of Golgi-related processes can lead to the development of novel compounds for various biomedical purposes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Obatoclax | 803712-67-6 | sc-507476 | 10 mg | $348.00 | ||
Obatoclax inhibits GOLT1B by binding to its active site and blocking it from catalyzing its substrate. | ||||||
ABT 737 | 852808-04-9 | sc-207242 | 2.5 mg | $204.00 | 54 | |
ABT-737 disrupts GOLT1B function by binding to its activesite, blocking its enzymatic activity. | ||||||
S63845 | 1799633-27-4 | sc-507518 | 1 mg | $150.00 | ||
S63845 works by specifically targeting GOLT1B's active site and inhibiting its enzymatic function. | ||||||
WEHI-539 | 1431866-33-9 | sc-507317 | 5 mg | $233.00 | ||
WEHI-539 disrupts GOLT1B activity by binding to its active site and blocking substrate processing. | ||||||
TW-37 | 877877-35-5 | sc-361387 sc-361387A | 10 mg 50 mg | $200.00 $860.00 | 2 | |
TW-37 inhibits GOLT1B through competitive binding at itsactive site, impeding its catalytic function. | ||||||
ABT 263 | 923564-51-6 | sc-207241 | 5 mg | $245.00 | 16 | |
Navitoclax interferes with GOLT1B activity by binding to its active site and blocking substrate conversion. | ||||||
A-1331852 | 1430844-80-6 | sc-507472 | 5 mg | $230.00 | ||
A-1331852 inhibits GOLT1B through non-competitive binding, disrupting its enzymatic function. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $116.00 $230.00 | 12 | |
Gossypol inhibits GOLT1B through competitive binding to its active site, reducing its enzymatic activity. | ||||||